NicOx S.A.

Nicox is engaged in the ophthalmic market. Co. markets several ophthalmic products in the United States and Europe with a portfolio of therapies and diagnostic tools that can help people to enhance their sight. Co. has developed naproxcinod, the first member of the Cyclooxygenase-Inhibiting Nitric Oxide-Donating (CINOD) class of anti-inflammatory agents, for the treatment of the signs and symptoms of osteoarthritis. Beyond naproxcinod, Co. has a pipeline containing multiple nitric oxide-donating NCEs, which are in clinical development with partners for the treatment of diseases, such as hypertension, glaucoma and Chronic Obstructive Pulmonary Disease (COPD).
  • TickerCOX
  • ISINFR0013018124
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance
Matthieu DRIOL

Analyse court terme - NICOX : Les prix baissent.

La tendance de fond est clairement orientée à la baisse. Les prix baissent à nouveau, mais le mouvement est devenu hésitant. Le prochain support est à 4,657 €. La tendance de fond serait remise en cause en cas de franchissement de 7,490 €.

Matthieu DRIOL

Short term view - NICOX : Falling prices.

The background trend is clearly bearish. Prices are falling again, but the movement has become hesitant. The next support is at €4.657. The background trend would be questioned should prices rise above €7.490.

Matthieu DRIOL

Analyse court terme - NICOX : La tendance de fond est clairement orientée à la baisse.

La tendance de fond est clairement orientée à la baisse. Le mouvement se poursuit. Le prochain objectif est à 4,657 €, puis 3,550 €. Le franchissement de 7,490 € remettrait en cause la suite de la baisse.

Matthieu DRIOL

Short term view - NICOX : The background trend is clearly bearish.

The background trend is clearly bearish. The movement goes on. The next target is at €4.657, then €3.550. Passing €7.490 would question the continuation of the fall.

Matthieu DRIOL

Medium term view - NICOX : The background trend is clearly bearish.

The background trend is clearly bearish. The movement goes on. The next target is at €4.70, then €3.55. Passing €13.70 would question the continuation of the fall.

Victor Floc’h

NICOX: Early proof of efficacy is emerging from NCX 4251 positive phase II dose finding trial | BUY | EUR18.5

NICOX - BUY | EUR18.5 Early proof of efficacy is emerging from NCX 4251 positive phase II dose finding trial 0.1% once daily dosage selected for a larger phase IIb study Early efficacy findings seem promising Blepharitis: a common condition and no approved treatment yet A licensing deal as an option to secure NCX 4251 future?

Feasibility Study Results in December to be a Catalyst for this Junior

Feasibility Study Results in December to be a Catalyst for this Junior